Research
Hormonal
Metformin reduces fasting plasma glucose by inhibiting hepatic gluconeogenesis via AMPK activation and reducing free fatty acid plasma concentration.
Metformin is the most common first-line medication for Type 2 Diabetes. It works by reducing the amount of sugar your liver makes and improving your body's sensitivity to insulin. Common side effects include stomach discomfort, which often improves over time.
GoodSupportsHIGH confidence
it is known that this biguanide acts by activation of the hepatic adenosine monophosphate-activated protein kinase, thus promoting an increased glucose uptake by the hepatocytes and also a complex alteration in mitochondrial enzyme apparatus leading to gluconeogenesis inhibition
Why this rating
Cited as the most frequently prescribed drug with established mechanisms.
Source
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
Raquel Vieira et al. · Pharmaceuticals · 2019
DOI 10.3390/ph12040152
narrative_reviewCited 184×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors lower blood glucose in Type 2 Diabetes by blocking renal glucose reabsorption, resulting in increased urinary glucose excretion without causing hypoglycemia.Good
- Sotagliflozin is a dual SGLT1/SGLT2 inhibitor that reduces postprandial glycemia by blocking intestinal glucose absorption and renal glucose reabsorption.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →